Fundraising Fox
アリヴェクシス㈱
Tokyo, JP · 6 known investors
Find your way into アリヴェクシス㈱
Sign up to see every warm intro you have to アリヴェクシス㈱
- Paths you didn't know you had: your email and LinkedIn already hold routes to the アリヴェクシス㈱ team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Alivexis is a drug discovery company that develops small molecule therapeutics targeting cancer, immune-inflammatory conditions, and rare diseases, leveraging computational platforms and disease biology expertise across operations in Japan and the US.
Founders & leadership
SR
S. Roy KimuraCofounder & CEOS. Roy Kimura has more than 20 years of experience in drug discovery R&D, business development, and consulting, including roles at Fortune 500 pharmaceutical companies and startup ventures, with expertise in pre-clinical drug discovery, computational modeling, and machine learning. He is cofounder and CEO of Alivexis, a drug discovery company developing small molecule therapeutics for cancer, immune-inflammatory conditions, and rare diseases.
KO
Kazuki OhnoCofounder & COO
Investors · 6
SMBC Venture Capital✓ confirmed by アリヴェクシス㈱Tokyo
How we know: the company's own site · Not right? Tell us
JIC Venture Growth Investmentslisted by JIC Venture Growth InvestmentsTokyo
How we know: JIC Venture Growth Investments's portfolio page · Not right? Tell us
Related companies · 4
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
ScynexisSCYNEXIS is a biopharmaceutical company focused on developing drug therapies for severe rare diseases, including anti-infective and antifungal treatments. The company serves patients in areas of unmet medical need within the pharmaceutical industry.
AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Companies working in the same space as アリヴェクシス㈱.
Frequently asked questions
- What does アリヴェクシス㈱ do?
- Alivexis is a drug discovery company that develops small molecule therapeutics targeting cancer, immune-inflammatory conditions, and rare diseases, leveraging computational platforms and disease biology expertise across operations in Japan and the US.
- Who founded アリヴェクシス㈱?
- アリヴェクシス㈱ was founded by S. Roy Kimura, Kazuki Ohno.
- Who are アリヴェクシス㈱'s investors?
- アリヴェクシス㈱'s investors include SMBC Venture Capital, DBJ Capital, Fast Track Initiative, JIC Venture Growth Investments, Mobile Internet Capital, Inc., UTokyo Innovation Platform Co. Ltd..
- Where is アリヴェクシス㈱ headquartered?
- アリヴェクシス㈱ is headquartered in Tokyo, JP.